Literature DB >> 11152527

DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques.

S Cherpelis1, I Shrivastava, A Gettie, X Jin, D D Ho, S W Barnett, L Stamatatos.   

Abstract

DNA immunization of macaques with the SF162DeltaV2 envelope elicited lymphoproliferative responses and potent neutralizing antibodies. The animals were depleted of their CD8(+) T lymphocytes and then challenged intravenously with SHIV162P4. Compared to unvaccinated animals, the vaccinated macaques had lower peak viremia levels, rapidly cleared plasma virus, and showed delayed seroconversion.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11152527      PMCID： PMC114060          DOI： 10.1128/JVI.75.3.1547-1550.2001

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  21 in total

1.  Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs.

Authors:  J M Harouse; A Gettie; R C Tan; J Blanchard; C Cheng-Mayer
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

2.  Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination.

Authors:  N L Letvin; D C Montefiori; Y Yasutomi; H C Perry; M E Davies; C Lekutis; M Alroy; D C Freed; C I Lord; L K Handt; M A Liu; J W Shiver
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 3.  Prime-boost immunization strategies against HIV.

Authors:  S W Barnett; J M Klinger; B Doe; C M Walker; L Hansen; A M Duliège; F M Sinangil
Journal:  AIDS Res Hum Retroviruses       Date:  1998-10       Impact factor: 2.205

4.  Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques.

Authors:  T Matano; R Shibata; C Siemon; M Connors; H C Lane; M A Martin
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

5.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.

Authors:  J E Schmitz; M J Kuroda; S Santra; V G Sasseville; M A Simon; M A Lifton; P Racz; K Tenner-Racz; M Dalesandro; B J Scallon; J Ghrayeb; M A Forman; D C Montefiori; E P Rieber; N L Letvin; K A Reimann
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

6.  Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.

Authors:  J F Richmond; F Mustafa; S Lu; J C Santoro; J Weng; M O'Connell; E M Fenyö; J L Hurwitz; D C Montefiori; H L Robinson
Journal:  Virology       Date:  1997-04-14       Impact factor: 3.616

7.  An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.

Authors:  L Stamatatos; C Cheng-Mayer
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

8.  An HIV type 2 DNA vaccine induces cross-reactive immune responses against HIV type 2 and SIV.

Authors:  M G Agadjanyan; N N Trivedi; S Kudchodkar; M Bennett; W Levine; A Lin; J Boyer; D Levy; K E Ugen; J J Kim; D B Weiner
Journal:  AIDS Res Hum Retroviruses       Date:  1997-12-10       Impact factor: 2.205

9.  Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.

Authors:  J F Richmond; S Lu; J C Santoro; J Weng; S L Hu; D C Montefiori; H L Robinson
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

10.  Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

Authors:  X Jin; D E Bauer; S E Tuttleton; S Lewin; A Gettie; J Blanchard; C E Irwin; J T Safrit; J Mittler; L Weinberger; L G Kostrikis; L Zhang; A S Perelson; D D Ho
Journal:  J Exp Med       Date:  1999-03-15       Impact factor: 14.307
View more
  28 in total

1.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

2.  Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles.

Authors:  Gillis Otten; Mary Schaefer; Catherine Greer; Maria Calderon-Cacia; Doris Coit; Jina Kazzaz; Angelica Medina-Selby; Mark Selby; Manmohan Singh; Mildred Ugozzoli; Jan zur Megede; Susan W Barnett; Derek O'Hagan; John Donnelly; Jeffrey Ulmer
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Authors:  S W Barnett; S Lu; I Srivastava; S Cherpelis; A Gettie; J Blanchard; S Wang; I Mboudjeka; L Leung; Y Lian; A Fong; C Buckner; A Ly; S Hilt; J Ulmer; C T Wild; J R Mascola; L Stamatatos
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 4.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

5.  Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.

Authors:  Indresh K Srivastava; Keating VanDorsten; Lucia Vojtech; Susan W Barnett; Leonidas Stamatatos
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 6.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

7.  Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery.

Authors:  Keith Mansfield; Sabine M Lang; Marie-Claire Gauduin; Hannah B Sanford; Jeffrey D Lifson; R Paul Johnson; Ronald C Desrosiers
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

8.  Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats.

Authors:  Gabriella Cseke; David W Wright; Sharon J Tollefson; Joyce E Johnson; James E Crowe; John V Williams
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

9.  Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Rogier W Sanders; Mika Vesanen; Norbert Schuelke; Aditi Master; Linnea Schiffner; Roopa Kalyanaraman; Maciej Paluch; Ben Berkhout; Paul J Maddon; William C Olson; Min Lu; John P Moore
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Elaine Kan; Michael Vajdy; Ying Lian; Susan Hilt; Loic Martin; Claudio Vita; Ping Zhu; Kenneth H Roux; Lucia Vojtech; David C Montefiori; John Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.